

CMV in Transplantation: Endpoints and Clinical Trial Designs

Meeting #2

Wednesday, May 06, 2015
 Philadelphia Marriott Downtown
 1201 Market Street Philadelphia, PA, 19107
 Independence Ballroom
 12:30PM - 7:30 PM

DRAFT AGENDA

12:30 PM	Welcome Reception and Check-In	Independence Ballroom Foyer
1:00 PM	Welcome & Introductions Brief Overview of Project Goals	Per Ljungman, <i>Karolinska Institutet</i> Veronica Miller, <i>HIV Forum</i>
1:05 PM	Update on FDA perspective	Jeff Murray, <i>FDA</i>
1:15 PM	Update on EMA perspective	Filip Josephson, <i>EMA</i>
1:25 PM	Session 1: CMV Diagnostics	Moderators Hans Hirsch, <i>University of Basel</i> Lesia Dropulic, <i>National Institute of Allergy and Infectious Disease</i>
1:25 PM	Updates from Diagnostics Working Group	Hans Hirsch, <i>University of Basel</i> Lesia Dropulic, <i>National Institute of Allergy and Infectious Disease</i> Veronica Miller, <i>HIV Forum</i>
1:35 PM	Discussion	All
2:35 PM	Session 2: CMV Clinical Definitions	Moderators Paul Griffiths, <i>University College London Medical</i> Per Ljungman, <i>Karolinska Institutet</i>
2:35 PM	Updated CMV Definitions	Per Ljungman, <i>Karolinska Institutet</i>
2:45 PM	Discussion	All
3:45 PM	Break	
4:15 PM	Session 3: CMV Clinical Trials	Moderator Atul Humar, <i>University of Toronto School of Medicine</i> Veronica Miller, <i>HIV Forum</i>
4:15 PM	Updates from Clinical Trials Working Group A. Literature review/ table of studies B. What are the strengths and limitations of existing data? C. What is needed to move forward on validating surrogacy? D. Opportunities for collaboration	Atul Humar, <i>University of Toronto School of Medicine</i>
4:25 PM	Discussion	All
5:25 PM	Session 4: Moving Forward	Moderators Per Ljungman, <i>Karolinska Institutet</i> Veronica Miller, <i>HIV Forum</i>

5:25 PM A. Publication plans All
B. Big picture: How far did we come; how far still to go,
are we following the right path?
C. Action items and Next Steps

6:00 PM **Networking Reception**

7:30 PM **Final Adjourn**
